Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 4Phase 2 3Phase NA 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3CNS 1Breast 1

Conditions

Neuroendocrine Tumors 4Serotonin Syndrome 1Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Octreotide 4Everolimus 4lanreotide 3pasireotide 2Carboplatin 2surufatinib 1lutetium Lu 177 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Diazoxide 1Cisplatin 1Cabergoline 164Cu-DOTATATE 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Octreotide × NET × Clear all
NCT03289741 2025-05-09

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Center

Phase 4 Completed
51 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

NCT05701241 2024-06-14

SAUNA

University Hospital, Antwerp

Phase 4 Recruiting
270 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT01789281 2021-06-11

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Novartis

Phase 4 Completed
34 enrolled 8 charts
EndocrineNET

Carcinoid Tumor, Neoplasms, Neuroendocrine Tumors

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated
10 enrolled
EndocrineNET

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡